Substance / Medication

Margetuximab

Overview

Active Ingredient
margetuximab
RxNorm CUI
2473851

Indications

Dosage and Administration (2.1) Clinical Studies (14.1) [seeand]. MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease

Labeler: TerSera Therapeutics LLCUpdated: 2025-02-11T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Royce Melanie, Osgood Christy L, Amatya Anup K et al. · Clin Cancer Res · 2022
PMID: 34916216ObservationalFull text (PMC)
Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series.
Mahtani Reshma, Harpalani Natasha, Yan Fengting et al. · Front Oncol · 2024
PMID: 39220641Case ReportFull text (PMC)
Margetuximab in HER2-positive metastatic breast cancer.
Gradishar William J, O'Regan Ruth, Rimawi Mothaffar F et al. · Future Oncol · 2023
PMID: 37170847Review
Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna Siti Muhamad, Wong Kah Keng · Mol Immunol · 2022
PMID: 36272249Review

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Margetuximab (substance)
SNOMED CT
1144474002
UMLS CUI
C4053695
RxNorm CUI
2473851
Labeler
TerSera Therapeutics LLC

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

1
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.